Nocturol, Inc. is a pharmaceutical developer focused on Nocturol™, an extended-release tablet being developed to reduce nighttime bathroom visits associated with nocturia. The company’s work centers on a prostaglandin-targeting formulation and has advanced through a Phase 2 double-blind clinical trial conducted in New York City and Long Island. Nocturol’s formulation was optimized with Pharm Ops at its GMP-licensed New Jersey facility, while the company builds partnerships for clinical, regulatory, and commercial development.
Nostrum Laboratories, IncNostrum Laboratories, Inc. develops, manufactures, and markets pharmaceutical medicines. Its stated mission emphasizes competitively priced quality products intended to benefit patients, and its listed portfolio includes prescription oral medicines in multiple dosage forms.BRYAN, OH
CeroveneCerovene develops and manufactures pharmaceutical dosage forms, helping partners take products from formulation concept through clinical and commercial launch. Based in Valley Cottage, New York, the company specializes in lifecycle management for existing medicines, including proprietary modified-release and coated-capsule technologies. Its team reports more than 90 approved prescription products developed by President and co-founder Manish S. Shah, along with dozens of FDA approvals for complex products.VALLEY COTTAGE, NY
Laxxon MedicalFounded in 2017 by pharmaceutical professionals, Laxxon Medical develops 3D screen-printed drug delivery systems through its proprietary SPID®-Technology. Headquartered in New York City with research and development facilities in Jena, Germany, the company works with pharmaceutical partners on oral dosage forms that can control how active ingredients are released, including projects aimed at making injectable therapies available by mouth. Its platform supports development from small clinical batches through production at up to 1.5 million units per day.NEW YORK, NY
Greene Street Pharmaceuticals, LLCBased in Pennsylvania, privately held Greene Street Pharmaceuticals develops and manufactures transdermal medicines, taking products from formulation through clinical studies and commercialization in-house. Its distinctive model combines a portfolio of Transdermal Innovative Products with small-scale direct manufacturing capacity of more than 3 million patches annually, focused on the 505(b)(2) pathway and on delivery options for patients with swallowing difficulties. The company operates an FDA-registered facility capable of production under cGMP standards.DOYLESTOWN, PA